Study of people with moderate Parkinson’s disease
Part of Brain & nervous system clinical trials.
This is an observational study, meaning it doesn’t test a new drug—researchers mainly follow people to better understand moderate Parkinson’s disease and who may be good candidates for future cell therapy. If you have moderate symptoms that aren’t well controlled with tablets, this study may help inform better future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 50 and 68 years old when you sign up
- You’ve been diagnosed with Parkinson’s disease and your doctor thinks it’s the typical (primary) form
- Your Parkinson’s symptoms are in the “moderate” range, based on your stage and symptom scores done by the study team
- Your tablets don’t fully control symptoms—your symptoms come and go (ON and OFF periods)
- You’ve had Parkinson’s disease for more than 5 years but no more than 12 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell treatment for Parkinson's disease. It involves injecting special cells into the brain to see if they can safely replace damaged cells and improve symptoms. It might help people who have had Parkinson's for several years and still respond well to medication.
This study is looking to improve how Parkinson’s and related brain conditions are identified and treated sooner. You may be asked to share your health information and provide blood or other samples, and possibly have procedures like a spinal fluid test or a small skin sample.
This study follows people with Parkinson’s disease, certain Parkinson-like conditions, and some people at higher risk. It helps researchers learn how these illnesses start and progress, which may lead to better earlier detection and care.
This trial uses new technology (like sensors or apps) to help diagnose and monitor Parkinson's disease early. Researchers want to see if a simple, widespread healthcare service model can improve care. Both people with Parkinson's and healthy volunteers are needed.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.